相关实验视频
Updated: Jan 11, 2026

07:27
Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
25.1K
呈现为耐火性心脏性休克和多器官衰竭的大型发红细胞瘤:一个案例报告
Pui Man Chung1, King Shing Yung1, Dominic So2
1Department of Radiology, Princess Margaret Hospital, Hong Kong.
Interventional radiology (Higashimatsuyama-shi (Japan)
|November 18, 2025
概括
一次大规模的染细胞瘤危机导致心脏性休克. 超辐射上腺动脉栓塞使患者稳定,降低了儿科胺分泌,并在手术前改善了血压.
科学领域:
- 内分泌学 在内分泌学.
- 干预性放射学 干预性放射学
- 心脏病学 心脏病学
背景情况:
- 乳腺红细胞瘤是一种罕见的上腺瘤,导致显著的发病率和死亡率.
- 乳腺红细胞瘤危机可能导致迅速恶化,包括心脏性休克和多器官衰竭.
- 管理是具有挑战性的,特别是在具有高外科风险的患者中.
研究的目的:
- 报告一个成功管理大型乳红细胞瘤的案例,呈现为危机.
- 在高风险患者中描述跨辐射上腺动脉栓塞的使用.
- 突出栓塞在稳定患有染细胞瘤危机的患者中的潜力.
主要方法:
- 一名中年妇女患有大左上腺体和染细胞瘤危机,接受了治疗.
- 由于腿部接入有限,外科手术风险高,进行了左侧偏远透射上腺动脉栓塞.
- 这项手术的目的是使瘤变质,并减少catecholamine的分泌.
主要成果:
- 患者出现了急性呼吸短促,耐火性心脏性休克和多器官衰竭.
- 多轴CT证实了大量的左上腺质量.
- 血清类甲基胺水平升高,证实了染细胞瘤.
- 在栓塞后,不稳定的血压有所改善.
- 患者逐渐康复,三周后接受了上腺切除术.
结论:
- 超辐射上腺动脉栓塞可以是一个可行的选择,以稳定高风险的患者与 pheochromocytoma危机.
- 这种微创的方法可以有效地减少瘤血管性和甲基荷胺分泌.
- 栓塞可以作为通往最终手术管理的桥梁,改善患者的治疗结果.
相关概念视频
Cardiopulmonary Resuscitation IV: Pharmacological Management
609
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
609
Cardiomyopathy II: Dilated Cardiomyopathy
449
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
449
Heart Failure II: Pathophysiology
693
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
693
Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
378
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
378
Heart Failure V: Medical Management
204
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
204

